These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38301886)

  • 1. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
    Holze F; Singh N; Liechti ME; D'Souza DC
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interactions involving classic psychedelics: A systematic review.
    Halman A; Kong G; Sarris J; Perkins D
    J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.
    Videira NB; Nair V; Paquet V; Calhoun D
    J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mescaline: The forgotten psychedelic.
    Vamvakopoulou IA; Narine KAD; Campbell I; Dyck JRB; Nutt DJ
    Neuropharmacology; 2023 Jan; 222():109294. PubMed ID: 36252614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
    Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
    Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
    Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ
    Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
    Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
    Halberstadt AL; Chatha M; Klein AK; McCorvy JD; Meyer MR; Wagmann L; Stratford A; Brandt SD
    Neuropharmacology; 2020 Aug; 172():107856. PubMed ID: 31756337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
    Dos Santos RG; Hallak JE; Baker G; Dursun S
    J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
    Rickli A; Moning OD; Hoener MC; Liechti ME
    Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the 5-HT
    Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
    Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Brief Historical Overview of Psychedelic Research.
    Geyer MA
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):464-471. PubMed ID: 38000715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin and Other Classic Psychedelics in Depression.
    Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D
    Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
    Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R
    J Psychopharmacol; 2023 Sep; 37(9):876-890. PubMed ID: 37572027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.